NASDAQ : LYCA
Lycia Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 26.4 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.52B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.56B |
| Enterprise Value | 1.41B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 18, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 57.68M |
| Shares Outstanding | 57.68M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.95% |
| Owned by Institutions (%) | 10.55% |
| Float | 33.84M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 350.64 |
| Forward PS | n/a |
| PB Ratio | 10.73 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 317.96 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.60 |
| Quick Ratio | 12.26 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,300.35 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -23.06% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $143,065 |
| Profits Per Employee | -$968,774 |
| Employee Count | 31 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -249,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 651,810 |
Shortselling
| Measure | Value |
|---|
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.44M |
| Gross Profit | 12.93M |
| Operating Income | -33.81M |
| Pretax Income | -30.28M |
| Net Income | -30.03M |
| EBITDA | -32.84M |
| EBIT | -33.81M |
| Loss Per Share | -$2.09 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 124.32M |
| Total Debt | 3.16M |
| Net Cash | 144.93M |
| Net Cash Per Share | $2.51 |
| Equity (Book Value) | 144.92M |
| Book Value Per Share | -9.02 |
| Working Capital | 117.58M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -33.75M |
| Capital Expenditures | -34,000 |
| Depreciation & Amortization | 974,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -33.79M |
| FCF Per Share | -$0.59 |
Margins
| Measure | Value |
|---|
| Gross Margin | 291.48% |
| Operating Margin | -762.32% |
| Pretax Margin | -682.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -7.76% |
| FCF Yield | -2.17% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1 |
| Piotroski F-Score | n/a |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |